OBJECTIVES: The aims of the presented study were to validate tools evaluating physical functioning (PF) after allogeneic hematopoietic stem cell transplantation (alloHSCT) and to analyze the impact of the clinical course on PF. METHODS: Forty patients undergoing alloHSCT were enrolled in a prospective trial which included evaluation of muscle strength (grip test, CITEC dynamometer), endurance (2-min walk test), anxiety and depression (Hospital Anxiety and Depression Scale), fatigue (Modified Fatigue Impact Scale and Brief Fatigue Inventory), and physical activity (Human Activity Profile--HAP) before (t1) and 1 (t2) and 3 (t3) months after alloHSCT. RESULTS: At t2, all patients showed a 6 % (p = 0.02) loss of muscle strength which was higher in patients with acute graft-versus-host disease (aGVHD) (12 %). While patients without aGVHD recovered at t3, the loss of muscle strength was progressive in patients with aGVHD. The grip test results correlated with the results of detailed measurement of muscle strength by CITEC dynamometer (r = 0.4-0.8, p = 0.05-0.001). Moreover, the HAP scores correlated with physical performance. CONCLUSION: The results demonstrate that loss of PF occurs during the first month followed by a regain during the subsequent 2 months in the absence of aGVHD. The HAP and the grip test may serve as surrogate marker for the strength loss in the course of aGVHD.
OBJECTIVES: The aims of the presented study were to validate tools evaluating physical functioning (PF) after allogeneic hematopoietic stem cell transplantation (alloHSCT) and to analyze the impact of the clinical course on PF. METHODS: Forty patients undergoing alloHSCT were enrolled in a prospective trial which included evaluation of muscle strength (grip test, CITEC dynamometer), endurance (2-min walk test), anxiety and depression (Hospital Anxiety and Depression Scale), fatigue (Modified Fatigue Impact Scale and Brief Fatigue Inventory), and physical activity (Human Activity Profile--HAP) before (t1) and 1 (t2) and 3 (t3) months after alloHSCT. RESULTS: At t2, all patients showed a 6 % (p = 0.02) loss of muscle strength which was higher in patients with acute graft-versus-host disease (aGVHD) (12 %). While patients without aGVHD recovered at t3, the loss of muscle strength was progressive in patients with aGVHD. The grip test results correlated with the results of detailed measurement of muscle strength by CITEC dynamometer (r = 0.4-0.8, p = 0.05-0.001). Moreover, the HAP scores correlated with physical performance. CONCLUSION: The results demonstrate that loss of PF occurs during the first month followed by a regain during the subsequent 2 months in the absence of aGVHD. The HAP and the grip test may serve as surrogate marker for the strength loss in the course of aGVHD.
Authors: Joachim Wiskemann; Peter Dreger; Rainer Schwerdtfeger; Andrea Bondong; Gerhard Huber; Nikolaus Kleindienst; Cornelia M Ulrich; Martin Bohus Journal: Blood Date: 2010-12-29 Impact factor: 22.113
Authors: H J Lee; B Oran; R M Saliba; D M Couriel; K Shin; P Massey; J Neumann; M de Lima; R Champlin; S Giralt Journal: Bone Marrow Transplant Date: 2006-07-03 Impact factor: 5.483
Authors: Kristin Pulewka; Daniel Wolff; Philipp Y Herzberg; Hildegard Greinix; Pia Heussner; Friederike H A Mumm; Stephanie von Harsdorf; Kathrin Rieger; Philipp Hemmati; Andreas Hochhaus; Inken Hilgendorf Journal: J Cancer Res Clin Oncol Date: 2017-04-19 Impact factor: 4.553
Authors: T Takekiyo; K Dozono; T Mitsuishi; S Nara; K Yoshida; Y Murayama; A Maeda; T Chaen; N Nakano; A Kubota; M Tokunaga; S Takeuchi; Y Takatsuka; A Utsunomiya Journal: Bone Marrow Transplant Date: 2016-03-21 Impact factor: 5.483
Authors: Stephanie J Lee; Daniel Wolff; Carrie Kitko; John Koreth; Yoshihiro Inamoto; Madan Jagasia; Joseph Pidala; Attilio Olivieri; Paul J Martin; Donna Przepiorka; Iskra Pusic; Fiona Dignan; Sandra A Mitchell; Anita Lawitschka; David Jacobsohn; Anne M Hall; Mary E D Flowers; Kirk R Schultz; Georgia Vogelsang; Steven Pavletic Journal: Biol Blood Marrow Transplant Date: 2015-03-19 Impact factor: 5.742
Authors: Janina Bujan Rivera; Rea Kühl; Ulrike Zech; Anne Hendricks; Thomas Luft; Peter Dreger; Birgit Friedmann-Bette; Theresa-Maria Betz; Joachim Wiskemann Journal: BMC Cancer Date: 2022-04-22 Impact factor: 4.638
Authors: Daniel C Souza; Fernando Wegner; Lucíola C M Costa; Luciana D Chiavegato; Adriana C Lunardi Journal: Braz J Phys Ther Date: 2017-04-09 Impact factor: 3.377